Journal article · 2025 · Open access
Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study
Vaccines, 13(12), 1219 · Published 2 December 2025 · DOI 10.3390/vaccines13121219
In brief
“Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study” is a 2025 journal article by Claudio Costantino and 22 co-authors, published in Vaccines. OpenAlex counts 11 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Vaccines.
- Citations
- 11
- Most cited in
- 2026 (11)
- Field-weighted impact
- 5.99
- References
- 30
- Authors
- 23
Abstract
Objectives: The introduction of universal prophylaxis with Nirsevimab represents a major innovation in preventing respiratory syncytial virus (RSV) infections in newborns. In Sicily, Nirsevimab administration began on 1 November 2024, for all newborns under one year and at-risk infants during the 2024–2025 season. This study assessed the real-world impact of this strategy in reducing RSV-related hospitalizations. Methods: This retrospective cohort study examined newborns residing in Sicily from 2015 to May 2025, evaluating hospitalization incidence rates attributable to RSV during the first year of life. RSV hospitalizations were identified using ICD-9 codes (079.6, 466.11, 480.1) in any diagnostic position. Incidence rates in the 2024–2025 season (intervention period) were compared with preceding seasons. Results: During the study period, 4431 RSV hospitalization cases occurred (19.84 cases per 1000 person-years), peaking in 2023–2024 (53.47 cases per 1000 person-years). A statistically significant 40% reduction in RSV hospitalizations was observed during the 2024–2025 season (October–April) compared with the preceding season, with a relative reduction ranging between 33.4% and 54.8% across sensitivity models. Conclusions: These results confirm the significant impact of the universal prophylaxis program in real-world practice, consistent with other European programs. These findings support universal RSV prevention strategies and provide insights for optimizing regional and national health policies.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Costantino, C., Amodio, E., Asciutto, R., Affranchi, C., Belbruno, F., Bonaccorso, N., Cilia, S., Contarino, F. M., Di Gaetano, V., Di Gregorio, F., Foresta, A., Furnari, R., Genna, F., Genovese, D., Giorgianni, G., Maida, C. M., Palmeri, S., Parrino, G., Piazza, A., . . . Vitale, F. M. (2025). Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study. Vaccines, 13(12), 1219. https://doi.org/10.3390/vaccines13121219
MLA 9
Costantino, Claudio, et al. “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study.” Vaccines, vol. 13, no. 12, 2025, p. 1219. https://doi.org/10.3390/vaccines13121219.
Chicago
Costantino, Claudio, Emanuele Amodio, Rosario Asciutto, Costanza Affranchi, Franco Belbruno, Nicole Bonaccorso, Sonia Cilia, et al. 2025. “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study.” Vaccines 13 (12): 1219. https://doi.org/10.3390/vaccines13121219.
Harvard
Costantino, C. et al. (2025) ‘Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study’, Vaccines, 13(12), p. 1219. doi:10.3390/vaccines13121219.
IEEE
C. Costantino et al., “Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study,” Vaccines, vol. 13, no. 12, p. 1219, 2025, doi: 10.3390/vaccines13121219.
BibTeX
@article{costantino2025impact,
title = {{Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study}},
author = {Costantino, Claudio and Amodio, Emanuele and Asciutto, Rosario and Affranchi, Costanza and Belbruno, Franco and Bonaccorso, Nicole and Cilia, Sonia and Contarino, Fabio Massimo and Di Gaetano, Vincenzo and Di Gregorio, Francesco and Foresta, Angelo and Furnari, Roberto and Genna, Flavio and Genovese, Dario and Giorgianni, Gabriele and Maida, Carmelo Massimo and Palmeri, Sara and Parrino, Giovanna and Piazza, Alessandra and Addario, Sebastiano Pollina and Tinervia, Giovanni and Tramuto, Fabio and Vitale, Francesco Maria},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {12},
pages = {1219},
doi = {10.3390/vaccines13121219},
url = {https://doi.org/10.3390/vaccines13121219}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- nirsevimab
- respiratory syncytial virus
- RSV bronchiolitis
- universal prophylaxis
- infants
- RSV hospitalization
- Sicily
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Costantino, C., Amodio, E., Asciutto, R., Affranchi, C., Belbruno, F., Bonaccorso, N., Cilia, S., Contarino, F. M., Di Gaetano, V., Di Gregorio, F., Foresta, A., Furnari, R., Genna, F., Genovese, D., Giorgianni, G., Maida, C. M., Palmeri, S., Parrino, G., Piazza, A., . . . Vitale, F. M. (2025). Impact of a Universal Nirsevimab Prevention Program Against Respiratory Syncytial Virus Bronchiolitis in Infants in Sicily (Italy) During the 2024–2025 Epidemic Season: A Retrospective Cohort Study. Vaccines, 13(12), 1219. https://doi.org/10.3390/vaccines13121219
How many times has this paper been cited?
11 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Vaccines: sign in and open the PDF from this page.
Who wrote this paper?
Claudio Costantino, Emanuele Amodio, Rosario Asciutto, Costanza Affranchi, Franco Belbruno, Nicole Bonaccorso, Sonia Cilia, Fabio Massimo Contarino, Vincenzo Di Gaetano, Francesco Di Gregorio, Angelo Foresta, Roberto Furnari and 11 more.
What is the DOI of this paper?
10.3390/vaccines13121219, permanently at https://doi.org/10.3390/vaccines13121219. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.